PD-1 positive tumor infiltrating lymphocytes and PD-L1 expressing tumor cells were seen in 18 of 42 cases (43%) of which 8 cases lacked other biologic targets including EGFR mutations, HER2, cMET, ALK, or ROS1 rearrangements [74]. This evidence concerns the gene ERBB2 and neoplasm.